Wednesday, February 10, 2010, 7:26am EST - Canadian Markets open in 2 hours and 4 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

NeurogesX, Inc. (NGSX)

 On Feb 9: 7.31 USD   0.00 (0.00%)  
MORE ON NGSX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
NeurogesX, Inc. (NGM:NGSX) Delayed quote dataEdit
Last Trade: 7.31 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 7.31
Open: N/A
Bid: 1.31 x 100
Ask: N/A
1y Target Est: 11.75
Day's Range: N/A - N/A
52wk Range: 1.06 - 9.20
Volume: 0
Avg Vol (3m): 87,249.2
Market Cap: 128.98M
P/E (ttm): N/A
EPS (ttm): -1.23
Div & Yield: N/A (N/A%)
NeurogesX, Inc. (NGSX)
1d  5d  3m  6m  1y  2y  5y 
 Add NGSX to Portfolio   Download Data

HEADLINES
• NEUROGESX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
EDGAR Online (Thu, Feb 4)
• NeurogesX to Present at BIO CEO & Investor Conference
PRNewswire (Thu, Feb 4)
• NeurogesX CFO names on COO role as well
at bizjournals.com (Thu, Feb 4)
• NeurogesX Announces Management Team Promotions
PRNewswire (Thu, Feb 4)
• [video] Trading Smallcap Biotech
at TheStreet.com (Mon, Feb 1)
• NEUROGESX INC Files SEC form 8-K/A, Change in Directors or Principal Officers
EDGAR Online (Thu, Jan 21)
• NEUROGESX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Thu, Jan 14)
• NeurogesX to Present at J.P. Morgan Health Care Conference
PRNewswire (Thu, Jan 7)
• NeurogesX to Present at Piper Jaffray Health Care Conference
PRNewswire (Tue, Nov 24)
• NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
PRNewswire (Tue, Nov 24)
More Headlines for NGSX...
ANALYST
EPS Est (next year) (Dec-09) : -1.31
EPS Est (in 2 years) (Dec-10) : -1.57
Avg Rec (current)*: 1.3
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
NeurogesX, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The company’s lead product candidate Qutenza, a dermal patch containing synthetic capsaicin, completed ...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices